BACKGROUND: We analyzed the significance of class III beta-tubulin (TUBB3) expression in curatively resected non-small cell lung cancer as a prognostic marker along with previously reported excision repair cross complementation group 1 (ERCC1). METHODS: One hundred and thirty-six consecutive patients were included in this retrospective study. Patients who received adjuvant chemotherapy were excluded. We used immunohistochemistry to evaluate TUBB3 and ERCC1 expression on tissue microarray in duplicate. Semiquantitative H score was used for the scoring of tumor staining. RESULTS: Sixty percent of patients had stage I disease, 17% stage II, 18% stage IIIA, and 5% stage IIIB. TUBB3 H score showed bimodal distribution with the minimum at the value of 4, which was used as a cutoff value for determination of TUBB3 positivity. TUBB3 was expressed in 60 patients (44%). Patients with a positive TUBB3 expression survived shorter than did the patients with a negative expression (5-year overall survival [OS] rate was 40% versus 61%; p = 0.005/5-year disease-free survival rate was 34% versus 55%; p = 0.024). ERCC1 expression showed tendency for prolonged OS without reaching statistical significance. A multivariate analysis that incorporated covariates including TUBB3 expression, age, stage, EGFR mutation status, histology, and ERCC1 expression showed that TUBB3 was an independent unfavorable prognostic factor for OS (hazard ratio 2.083; p = 0.008) and relapse free survival (hazard ratio 1.978; p = 0.020). CONCLUSIONS: TUBB3 expression is an independent unfavorable prognostic marker in patients with curatively resected non-small cell lung cancer who did not receive adjuvant chemotherapy.
BACKGROUND: We analyzed the significance of class III beta-tubulin (TUBB3) expression in curatively resected non-small cell lung cancer as a prognostic marker along with previously reported excision repair cross complementation group 1 (ERCC1). METHODS: One hundred and thirty-six consecutive patients were included in this retrospective study. Patients who received adjuvant chemotherapy were excluded. We used immunohistochemistry to evaluate TUBB3 and ERCC1 expression on tissue microarray in duplicate. Semiquantitative H score was used for the scoring of tumor staining. RESULTS: Sixty percent of patients had stage I disease, 17% stage II, 18% stage IIIA, and 5% stage IIIB. TUBB3 H score showed bimodal distribution with the minimum at the value of 4, which was used as a cutoff value for determination of TUBB3 positivity. TUBB3 was expressed in 60 patients (44%). Patients with a positive TUBB3 expression survived shorter than did the patients with a negative expression (5-year overall survival [OS] rate was 40% versus 61%; p = 0.005/5-year disease-free survival rate was 34% versus 55%; p = 0.024). ERCC1 expression showed tendency for prolonged OS without reaching statistical significance. A multivariate analysis that incorporated covariates including TUBB3 expression, age, stage, EGFR mutation status, histology, and ERCC1 expression showed that TUBB3 was an independent unfavorable prognostic factor for OS (hazard ratio 2.083; p = 0.008) and relapse free survival (hazard ratio 1.978; p = 0.020). CONCLUSIONS:TUBB3 expression is an independent unfavorable prognostic marker in patients with curatively resected non-small cell lung cancer who did not receive adjuvant chemotherapy.
Authors: Alexander Quaas; Amir-Hossein Rahvar; Christoph Burdelski; Christina Koop; Christian Eichelberg; Michael Rink; Roland Dahlem; Thorsten Schlomm; Maria Christina Tsourlakis; Ronald Simon; Sarah Minner; Guido Sauter; Stefan Steurer Journal: World J Urol Date: 2014-12-21 Impact factor: 4.226
Authors: T Reiman; R Lai; A S Veillard; E Paris; J C Soria; R Rosell; M Taron; S Graziano; R Kratzke; L Seymour; F A Shepherd; J P Pignon; P Sève Journal: Ann Oncol Date: 2011-04-06 Impact factor: 32.976
Authors: Deepak Kanojia; Wojciech K Panek; Alex Cordero; Jawad Fares; Annie Xiao; Solomiia Savchuk; Krishan Kumar; Ting Xiao; Katarzyna C Pituch; Jason Miska; Peng Zhang; Kwok-Ling Kam; Craig Horbinski; Irina V Balyasnikova; Atique U Ahmed; Maciej S Lesniak Journal: Sci Transl Med Date: 2020-08-26 Impact factor: 17.956